Resistance to antimony and treatment failure in human Leishmania (Viannia) infection

The Journal of Infectious Diseases
Ricardo RojasNancy G Saravia

Abstract

Failure of antimonial therapy has been increasingly reported in anthroponotic visceral leishmaniasis and in cutaneous disease. The role of drug resistance in treatment failure has been difficult to ascertain because therapeutic response is multifactorial, and the efficacy of antimonial drugs depends on an effective immune response. In this study, we sought to determine whether standard treatment selects for resistant organisms and whether drug resistance contributes to treatment failure. We evaluated the susceptibility to antimony of 19 strains isolated before treatment with meglumine antimoniate and 21 strains isolated at treatment failure from 20 patients. The 50% effective dose (ED50) of antimony in the form of additive-free meglumine antimoniate was determined for intracellular amastigotes in human promonocytic U-937 cells. Before treatment, 16% of strains (3/19) showed primary resistance (ED50 of >128 microg Sb/mL), whereas 84% (16/19) were susceptible (ED50 of <20 microg Sb/mL). However, 88% of susceptible strains (14/16) had ED90 values of >128 microg Sb/mL. At treatment failure, 40% of strains (8/20) were resistant. Secondary resistance was documented in 4 patients. Primary and secondary resistance to antimony can contr...Continue Reading

Citations

Mar 29, 2007·Parasitology Research·L F D PasseroM D Laurenti
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alejandro Llanos-CuentasFrancois Chappuis
Dec 20, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Laurence LachaudMarc Ouellette
Oct 1, 2008·Antimicrobial Agents and Chemotherapy·Diego A Goyeneche-PatinoNancy G Saravia
Mar 25, 2009·Antimicrobial Agents and Chemotherapy·Philippe LeprohonMarc Ouellette
Apr 21, 2012·Journal of Clinical Microbiology·Olga FernándezNancy Gore Saravia
Dec 17, 2011·Journal of Tropical Medicine·Fakhri JeddiCharles Mary
Sep 22, 2010·PLoS Neglected Tropical Diseases·Ibeth RomeroNancy Gore Saravia
Jun 2, 2011·PLoS Neglected Tropical Diseases·Rubens L do Monte-NetoMarc Ouellette
Apr 5, 2013·PLoS Neglected Tropical Diseases·Piero OlliaroJorge Alvar
Sep 8, 2012·Future Microbiology·Alexandra K MarrW Robert McMaster
Nov 18, 2014·BMC Research Notes·Barnali WaughRahul Banerjee
Apr 1, 2011·Travel Medicine and Infectious Disease·P P A M van ThielP A Kager
Apr 30, 2010·International Journal of Antimicrobial Agents·Ruchi SinghPoonam Salotra
Apr 13, 2010·Enfermedades infecciosas y microbiología clínica·Anna GirbauEsmeralda de la Banda
Mar 23, 2010·Journal of the American Academy of Dermatology·Panagiotis MitropoulosMindy Durkin-Konidas
Jan 9, 2010·Journal of Proteomics·Patricia CuervoJose B De Jesus
Sep 22, 2007·Acta Tropica·Valdir Sabbaga AmatoAntonio Carlos Nicodemo
Jan 8, 2009·International Journal of Dermatology·Wendy F van der MeideRudy F M Lai A Fat
Jan 24, 2008·International Journal of Dermatology·Felipe Francisco TuonVicente Amato Neto
Oct 31, 2009·Tropical Medicine & International Health : TM & IH·Rogéria C Zauli-NascimentoSilvia R B Uliana
Oct 15, 2013·Chemical Biology & Drug Design·Vivian I BonanoSilvia R B Uliana
Mar 28, 2012·Molecular and Biochemical Parasitology·John WalkerNancy G Saravia
Dec 30, 2014·Parasitology International·Somayeh GhotlooAli Rostami
Dec 17, 2014·European Journal of Medicinal Chemistry·Alex Evangelista do AmaralGuilhermina Rodrigues Noleto
Jul 9, 2011·Molecular and Biochemical Parasitology·Neha BiyaniRentala Madhubala
Jun 3, 2015·Current Infectious Disease Reports·Adrienne J Showler, Andrea K Boggild
Dec 1, 2012·International Journal for Parasitology. Drugs and Drug Resistance·Denis SerenoKhatima Aït-Oudhia
Oct 5, 2010·Parasitology International·Elodie GazanionDenis Sereno

❮ Previous
Next ❯

Related Concepts